[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2019

August 2019 | 60 pages | ID: IABE7B897EEEN
DelveInsight

US$ 1,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 Hours

"Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Idiopathic CD4+ Lymphocytopenia pipeline landscape is provided which includes the disease overview and Idiopathic CD4+ Lymphocytopenia treatment guidelines. The assessment part of the report embraces, in depth Idiopathic CD4+ Lymphocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic CD4+ Lymphocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Idiopathic CD4+ Lymphocytopenia Understanding

According to the US Centers for Disease Control and Prevention (CDC), Idiopathic CD4 lymphocytopenia (ICL) is a rare primary immunodeficiency disorder characterized by persistent CD4 T-cell lymphopenia (less than 300 cells/µL on multiple occasions or of less than 20% of total T cells on more than one occasion) with no evidence of human immunodeficiency virus (HIV) infection or no association with any other underlying primary or secondary immune deficiency or therapy associated with depressed levels of CD4 T cells. The clinical presentation can range from serious opportunistic infections to incidentally diagnosed asymptomatic individuals. Patients typically present opportunistic infections with cryptococcal, mycobacterial, candidal, varicella zoster virus infections and without the evidence of HIV infection. Progressive multifocal leukoencephalopathy, malignancies mainly lymphoproliferative disorders, or autoimmune disorders are commonly associated with lymphocytopenia. ICL is a condition of unknown etiology and is considered a heterogeneous syndrome possibly encompassing different disorders sharing the common feature of reduced circulating CD4 T-cell counts. Most of the knowledge about ICL comes from scattered case reports due to rarity of this condition and patients with ICL appear to be epidemiologically, clinically, and immunologically heterogeneous.

Idiopathic CD4+ Lymphocytopenia Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Idiopathic CD4+ Lymphocytopenia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Idiopathic CD4+ Lymphocytopenia pipeline report covers 3+ companies. Some of the key players include NeoImmuneTech (Hyleukin-7) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Idiopathic CD4+ Lymphocytopenia Analytical Perspective by DelveInsight
  • In-depth Idiopathic CD4+ Lymphocytopenia Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Idiopathic CD4+ Lymphocytopenia Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Idiopathic CD4+ Lymphocytopenia report provides an overview of therapeutic pipeline activity for Idiopathic CD4+ Lymphocytopenia across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Idiopathic CD4+ Lymphocytopenia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Idiopathic CD4+ Lymphocytopenia Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Idiopathic CD4+ Lymphocytopenia
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Idiopathic CD4+ Lymphocytopenia to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Idiopathic CD4+ Lymphocytopenia R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Idiopathic CD4+ Lymphocytopenia in licensing and out licensing strategies by identifying prospective partners with progressing projects for Idiopathic CD4+ Lymphocytopenia to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. IDIOPATHIC CD4+ LYMPHOCYTOPENIA

2.1. Idiopathic CD4+ Lymphocytopenia Disease Overview
2.2. Idiopathic CD4+ Lymphocytopenia History
2.3. Idiopathic CD4+ Lymphocytopenia Symptoms
2.4. Idiopathic CD4+ Lymphocytopenia Causes
2.5. Idiopathic CD4+ Lymphocytopenia Pathophysiology
2.6. Idiopathic CD4+ Lymphocytopenia Diagnosis
  2.6.1. Diagnostic Guidelines

3. IDIOPATHIC CD4+ LYMPHOCYTOPENIA CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. IDIOPATHIC CD4+ LYMPHOCYTOPENIA- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Idiopathic CD4+ Lymphocytopenia companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Idiopathic CD4+ Lymphocytopenia Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. IDIOPATHIC CD4+ LYMPHOCYTOPENIA PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. IDIOPATHIC CD4+ LYMPHOCYTOPENIA-PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Hyleukin-7- NeoImmuneTech
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
To be continued in the report…………………………

7. RECENT TECHNOLOGIES

8. IDIOPATHIC CD4+ LYMPHOCYTOPENIA KEY COMPANIES

8.1. Revimmune SAS
8.2. Genexine
8.3. NeoImmuneTech

9. IDIOPATHIC CD4+ LYMPHOCYTOPENIA KEY PRODUCTS

9.1. Interleukin 7
9.2. Efineptakin alfa
9.3. Hyleukin-7

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. IDIOPATHIC CD4+ LYMPHOCYTOPENIA- UNMET NEEDS

12. IDIOPATHIC CD4+ LYMPHOCYTOPENIA- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Idiopathic CD4+ Lymphocytopenia Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Idiopathic CD4+ Lymphocytopenia companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

Revimmune SAS
Genexine
Merck & Co
Biogen Idec
Millennium Pharmaceuticals
Ono Pharmaceutical
Chiron
Bayer
Sanofi


More Publications